NervGen Pharma Corp. (NGEN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

NervGen Pharma Corp. (NGEN) closed at USD 1.57 on 2026-10-14, a change of -40.9 % over the past year, with a market capitalization of USD 174.19M.

NervGen Pharma Corp. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

NervGen Pharma Corp. key figures

Previous close

USD 1.57 (2026-10-14)

1-year change

-40.9 %

Market cap

USD 174.19M

Enterprise value

USD 87.4M

P/E ratio (trailing)

-2.84

P/E ratio (forward)

-4.78

EPS (trailing)

-0.57

EPS (forward)

-0.34

PEG ratio

n/a

Price to book

14.21

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.82

Employees

9

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About NervGen Pharma Corp.

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for NervGen Pharma Corp. and compare it with other stocks.